...
btai-img

BioXcel Therapeutics Inc, Common Stock

BTAI

NAQ

$0.4078

-$0.02

(-4.65%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$20.79M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
440.49K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
0.29
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$0.4 L
$4.17 H
$0.4078

About BioXcel Therapeutics Inc, Common Stock

BioXcel Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. Its commercial product, IGALMI, a sublingual film formulation of dexmedetomidine for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. The company also continues to conduct clinical trials evaluating BXCL501 for the acute treatment of agitation in Alzheimer's disease patients, and for adjunctive treatment of patients with major depressive disorder, as well as in the community for agitation associated with bipolar disorders and schizophrenia. In addition, it is developing BXCL502 as a potential therapy for chronic agitation in dementia; and BXCL701, an investigational, orally innate immunity activator for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors; BXCL503, a drug candidate to target apathy in dementia; and BXCL504, a drug candidate to target aggression in dementia. BioXcel Therapeutics, Inc. was incorporated in 2017 and is headquartered in New Haven, Connecticut. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameBTAISectorS&P500
1-Week Return-12.07%0.67%0.49%
1-Month Return-36.77%0.26%5.96%
3-Month Return-34.22%-6.21%9.35%
6-Month Return-75.87%1.69%14.4%
1-Year Return-89.32%11.41%32.23%
3-Year Return-98.1%12.87%33.15%
5-Year Return-93.89%48.89%95.23%
10-Year Return-96.3%109.26%191.11%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue-24.30-375.00K1.38M[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":27.17,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Cost of Revenue156.00K188.00K297.00K20.00K1.26M[{"date":"2019-12-31","value":12.38,"profit":true},{"date":"2020-12-31","value":14.92,"profit":true},{"date":"2021-12-31","value":23.57,"profit":true},{"date":"2022-12-31","value":1.59,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Gross Profit(156.00K)24.30(297.00K)355.00K120.00K[{"date":"2019-12-31","value":-43.94,"profit":false},{"date":"2020-12-31","value":0.01,"profit":true},{"date":"2021-12-31","value":-83.66,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":33.8,"profit":true}]
Gross Margin-100.00%-94.67%8.70%[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":94.67,"profit":true},{"date":"2023-12-31","value":8.7,"profit":true}]
Operating Expenses33.60M82.30M106.94M160.00M171.90M[{"date":"2019-12-31","value":19.55,"profit":true},{"date":"2020-12-31","value":47.87,"profit":true},{"date":"2021-12-31","value":62.21,"profit":true},{"date":"2022-12-31","value":93.08,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Operating Income(33.60M)(82.30M)(106.94M)(159.65M)(171.78M)[{"date":"2019-12-31","value":-3360100000,"profit":false},{"date":"2020-12-31","value":-8229700000,"profit":false},{"date":"2021-12-31","value":-10693500000,"profit":false},{"date":"2022-12-31","value":-15964500000,"profit":false},{"date":"2023-12-31","value":-17178200000,"profit":false}]
Total Non-Operating Income/Expense-256.00K8.00K(11.80M)(13.88M)[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":3.13,"profit":true},{"date":"2022-12-31","value":-4608.2,"profit":false},{"date":"2023-12-31","value":-5422.27,"profit":false}]
Pre-Tax Income(32.97M)(82.17M)(106.93M)(165.76M)(179.05M)[{"date":"2019-12-31","value":-3296800000,"profit":false},{"date":"2020-12-31","value":-8216900000,"profit":false},{"date":"2021-12-31","value":-10693100000,"profit":false},{"date":"2022-12-31","value":-16575700000,"profit":false},{"date":"2023-12-31","value":-17905300000,"profit":false}]
Income Taxes(633.00K)(161.00K)(301.00K)6.09M150.10K[{"date":"2019-12-31","value":-10.39,"profit":false},{"date":"2020-12-31","value":-2.64,"profit":false},{"date":"2021-12-31","value":-4.94,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":2.46,"profit":true}]
Income After Taxes-(82.01M)(106.63M)(171.85M)(179.20M)[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-8200800000,"profit":false},{"date":"2021-12-31","value":-10663000000,"profit":false},{"date":"2022-12-31","value":-17184900000,"profit":false},{"date":"2023-12-31","value":-17920310500,"profit":false}]
Income From Continuous Operations(32.97M)(82.32M)(106.93M)(165.76M)(211.60M)[{"date":"2019-12-31","value":-3296800000,"profit":false},{"date":"2020-12-31","value":-8232400000,"profit":false},{"date":"2021-12-31","value":-10693100000,"profit":false},{"date":"2022-12-31","value":-16575700000,"profit":false},{"date":"2023-12-31","value":-21160500000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income(32.34M)(82.01M)(106.63M)(171.85M)(179.05M)[{"date":"2019-12-31","value":-3233500000,"profit":false},{"date":"2020-12-31","value":-8200800000,"profit":false},{"date":"2021-12-31","value":-10663000000,"profit":false},{"date":"2022-12-31","value":-17184900000,"profit":false},{"date":"2023-12-31","value":-17905300000,"profit":false}]
EPS (Diluted)(2.02)(3.79)(4.08)(5.91)(6.15)[{"date":"2019-12-31","value":-202,"profit":false},{"date":"2020-12-31","value":-379,"profit":false},{"date":"2021-12-31","value":-408,"profit":false},{"date":"2022-12-31","value":-591,"profit":false},{"date":"2023-12-31","value":-615,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

BTAI
Cash Ratio 1.58
Current Ratio 1.87
Quick Ratio 1.81

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

BTAI
ROA (LTM) -63.62%
ROE (LTM) -1766.94%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

BTAI
Debt Ratio Lower is generally better. Negative is bad. 2.75
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. -1.75

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

BTAI
Trailing PE NM
Forward PE NM
P/S (TTM) 8.65
P/B 3.97
Price/FCF NM
EV/R 37.06
EV/Ebitda NM

FAQs

What is BioXcel Therapeutics Inc share price today?

BioXcel Therapeutics Inc (BTAI) share price today is $0.4078

Can Indians buy BioXcel Therapeutics Inc shares?

Yes, Indians can buy shares of BioXcel Therapeutics Inc (BTAI) on Vested. To buy BioXcel Therapeutics Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in BTAI stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of BioXcel Therapeutics Inc be purchased?

Yes, you can purchase fractional shares of BioXcel Therapeutics Inc (BTAI) via the Vested app. You can start investing in BioXcel Therapeutics Inc (BTAI) with a minimum investment of $1.

How to invest in BioXcel Therapeutics Inc shares from India?

You can invest in shares of BioXcel Therapeutics Inc (BTAI) via Vested in three simple steps:

  • Click on Sign Up or Invest in BTAI stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in BioXcel Therapeutics Inc shares
What is BioXcel Therapeutics Inc 52-week high and low stock price?

The 52-week high price of BioXcel Therapeutics Inc (BTAI) is $4.17. The 52-week low price of BioXcel Therapeutics Inc (BTAI) is $0.4.

What is BioXcel Therapeutics Inc price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of BioXcel Therapeutics Inc (BTAI) is

What is BioXcel Therapeutics Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of BioXcel Therapeutics Inc (BTAI) is 3.97

What is BioXcel Therapeutics Inc dividend yield?

The dividend yield of BioXcel Therapeutics Inc (BTAI) is 0.00%

What is the Market Cap of BioXcel Therapeutics Inc?

The market capitalization of BioXcel Therapeutics Inc (BTAI) is $20.79M

What is BioXcel Therapeutics Inc’s stock symbol?

The stock symbol (or ticker) of BioXcel Therapeutics Inc is BTAI

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top